Prolia (60 mg/ml) Injection

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Prolia (60 mg/ml) Injection contains denosumab, a monoclonal antibody that binds RANKL, a protein responsible for bone loss. It is prescribed for osteoporosis in post-menopausal women and in men at increased risk of fractures, helping to strengthen bone and reduce fracture risk when given regularly.

Active ingredient
Denosumab
Strength
60 mg/ml
Dosage form
Solution for injection (pre-filled syringe)
Therapeutic class
RANKL inhibitor (monoclonal antibody)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with denosumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Treatment of osteoporosis in post-menopausal women
  • Treatment of bone loss in men at increased risk of fractures
  • Described as strengthening bone and reducing the risk of fractures when used regularly
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Given as a subcutaneous injection by a doctor or nurse, typically at a fixed interval; timing should be kept consistent for best effect
  • The full course should not be stopped early without prescriber advice
  • Calcium and vitamin D supplementation may be advised alongside treatment

Described Side Effects

Commonly described side effects include:

  • Bone, muscle, or joint pain
  • Rash or eczema
  • Nerve pain and headache
  • Back pain and joint pain
  • Constipation; hair loss

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • Complete medical records, including dental history, should be shared with the prescriber
  • Pregnancy or breastfeeding should be discussed before treatment
  • All current medicines should be disclosed to the prescriber
  • Adequate calcium and vitamin D intake may be required during treatment

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling, Prolia contains denosumab and is used for osteoporosis in post-menopausal women and men at increased fracture risk. SDO Pharma has not independently verified these claims.

As a subcutaneous injection given by a doctor or nurse at the interval set by the prescriber, with consistent timing between doses.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services